Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Advanz Gets European Heft, Portfolio Assets In Correvio Buyout

Executive Summary

Deal Snapshot: Building portfolio and commercial infrastructure in Europe, Advanz gets both at a modest price in acquiring Correvio.

You may also be interested in...



Deal Watch: Coronavirus Collaborations Reflect Industry’s Full Press Pandemic Response

Deals involving Hoth/Voltron, Vir/Xencor, Akers/Premas, WPD/CNS address coronavirus outbreak. Separately, Roche and Forge hope to develop a novel antibiotic for Gram-negative infections using the LpxC enzyme.

Deal Watch: Lilly, AbCellera Partner To Attempt Rapid COVID-19 Antibody Development

Partnership will combine AbCellera’s screening of antibodies to the virus with Lilly’s development, commercial capabilities. Vir adds Biogen tie-up to its ongoing coronavirus efforts.

Keeping Track Of The US FDA's Final Novel Approvals, CRLs Of 2019

The latest news on novel drug approvals and complete response letters from our US FDA Performance Tracker.

Related Content

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

SC141849

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel